Biochemical mechanisms of drug action: what does it take for success?

@article{Swinney2004BiochemicalMO,
  title={Biochemical mechanisms of drug action: what does it take for success?},
  author={David C. Swinney},
  journal={Nature Reviews Drug Discovery},
  year={2004},
  volume={3},
  pages={801-808}
}
  • D. Swinney
  • Published 1 September 2004
  • Biology, Medicine
  • Nature Reviews Drug Discovery
Drug discovery is extremely difficult. There are many unanticipated scientific, medical and business challenges to every drug discovery programme. It is important to increase our understanding of the fundamental properties of effective drugs so that we can anticipate potential problems in developing new agents. This article addresses potential drug discovery and development risks associated with the biochemical mechanism of drug action, and proposes simple rules to minimize these risks. 

Figures, Tables, and Topics from this paper

Paper Mentions

Target-drug interactions: first principles and their application to drug discovery.
TLDR
The basic principles of kinetics and thermodynamics of target-drug binding within the context of drug discovery are introduced and the best practices in the triage and chemical optimization towards clinical candidates with maximal in vivo efficacy devoid of adverse events are discussed. Expand
Mechanism of Action Assays for Enzymes
Many drugs are inhibitors of enzymes involved in mediating the disease processes. Understanding the mechanism of action (MOA) of the target enzyme is critical in early discovery and development ofExpand
Opportunities to minimise risk in drug discovery and development
  • D. Swinney
  • Biology, Medicine
  • Expert opinion on drug discovery
  • 2006
The last decade has seen great advances in defining the molecular components of physiological pathways with the sequencing of the human genome and advances in protein structure analysis. However,Expand
Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
TLDR
Evidence suggests that there is a reduced risk for the development of resistance against covalent drugs, which is a major challenge in areas such as oncology and infectious disease. Expand
Rethinking mechanisms of drug discovery
TLDR
Overreliance on simplistic, target-centered screens early in drug development may inadvertently select for compounds destined to fail in late-stage trials, a Roche team has concluded. Expand
Mechanistic enzymology in drug discovery: a fresh perspective
TLDR
This review highlights the rationale for conducting high-quality mechanistic enzymology studies and considers the added value in combining such studies with orthogonal biophysical methods. Expand
Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases
  • D. Swinney
  • Medicine
  • Clinical pharmacology and therapeutics
  • 2016
Only 10–15 first‐in‐class new medicines are approved each year by the global pharmaceutical industry for all diseases, of which less than a third is for rare (orphan) diseases. The drug discoveryExpand
Drugs, their targets and the nature and number of drug targets
TLDR
This work considers the nature of drug targets, and by classifying known drug substances on the basis of the discussed principles it provides an estimation of the total number of current drug targets. Expand
Failure Modes in Anticancer Drug Discovery and Development
TLDR
This chapter will discuss reasons why failures occur in the clinical development stages of drug development. Expand
Recent advances in phenotypic drug discovery
TLDR
In this short review, recent advances are noted for the implementation and de-risking of PDD (for compound library selection, biomarker development, mechanism identification, and safety studies) and the potential for artificial intelligence. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
The druggable genome
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceuticalExpand
Granisetron: relating pharmacology to clinical efficacy
  • P. Blower
  • Medicine
  • Supportive Care in Cancer
  • 2002
TLDR
The pharmacology of granisetron suggests that it may have an improved side-effect and tolerability profile, a lower risk of drug interactions and a longer duration of action than other 5-HT3-receptor antagonists. Expand
Enzyme Inhibition in Open Systems
TLDR
Investigations of the open system behavior of reversible dead-end inhibitors indicated that substrate-competitive inhibition may often be an inappropriate basis for design of potential therapeutic agents, and chemical analogs of pathogen-specific enzymic reaction products rather than analogS of substrates provide a promising basis for the systematic design of such uncompetitive inhibitors. Expand
The Molecular Pharmacology of SERMs
  • D. McDonnell
  • Medicine, Biology
  • Trends in Endocrinology & Metabolism
  • 1999
TLDR
Compounds of this class, which function as estrogens in the skeletal system but oppose estrogen action in the breast, are the first step in developing the perfect hormone replacement therapy. Expand
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.
TLDR
A unique class of diarylheterocyclic inhibitors has been developed that is highly selective for COX-2 by virtue of distinct inhibitory mechanisms for each isoenzyme. Expand
A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
TLDR
A new series of potent antagonists was designed, designed from the structure of the novel nonpeptide AT1 receptor antagonist DuP 753 (losartan), and the central imidazole nucleus was replaced by the dihydroimidazol-4-one structure, which was recently shown to also be active in cynomolgus monkeys both intravenously and orally. Expand
Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
TLDR
The microsomal assay was more sensitive to inhibition than cell-based assays and allowed the detection of inhibitory effects on COX-1 for all NSAIDs and selective COx-2 inhibitors examined with discrimination of their potency under conditions of limited availability of arachidonic acid. Expand
Progesterone receptor and the mechanism of action of progesterone antagonists
TLDR
Both published and unpublished data supporting the concept of two types of progesterone antagonists are discussed, suggesting that in addition to behaving by classical competitive mechanisms these compounds (in particular Type II) may exhibit additional activity as transrepressors of PR in the same cell bound to hormone agonist. Expand
Evaluation of inhibition of the carbenicillin‐hydrolyzing β‐lactamase PSE‐4 by the clinically used mechanism‐based inhibitors
Characterization of the biochemical steps in the inactivation chemistry of clavulanic acid, sulbactam and tazobactam with the carbenicillin‐hydrolyzing β‐lactamase PSE‐4 from Pseudomonas aeruginosaExpand
Novel Mechanisms of Action of Three Antiepileptic Drugs, Vigabatrin, Tiagabine, and Topiramate
TLDR
Three currently available drugs are of special interest because they have novel mechanisms of action and are especially effective for partial onset seizures, and Vigabatrin is a selective and irreversible GABA-transaminase inhibitor that greatly increases whole-brain levels of GABA. Expand
...
1
2
3
4
5
...